Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Blood|March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabJohn C Byrd, Peter Hillmen, Susan O'Brien, et al.
Blood|August 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLOthman Al-Sawaf, Moritz Fürstenau, Adam Giza, et al.
Leukemia|December 22, 2018
Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophiliaNicholas C P Cross, Yvette Hoade, William J Tapper, et al.
The New England Journal of Medicine|June 3, 2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaJohn C Byrd, Jennifer R Brown, Susan O'Brien, et al.
The Lancet. Oncology|May 31, 2024
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialMoritz Fürstenau, Arnon P Kater, Sandra Robrecht, et al.
The New England Journal of Medicine|May 10, 2023
First-Line Venetoclax Combinations in Chronic Lymphocytic LeukemiaBarbara Eichhorst, Carsten U Niemann, Arnon P Kater, et al.
Haematologica|August 3, 2019
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemiaFary Diop, Riccardo Moia, Chiara Favini, et al.
Blood|May 12, 2023
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinationsMoritz Fürstenau, Yvonne J Thus, Sandra Robrecht, et al.
The New England Journal of Medicine|December 8, 2025
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic LeukemiaOthman Al-Sawaf, Janina Stumpf, Can Zhang, et al.
Blood|March 30, 2026
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trialMoritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht, et al.
Pageof 4